# Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma

> **NCT02163057** · PHASE1,PHASE2 · COMPLETED · sponsor: **Inovio Pharmaceuticals** · enrollment: 22 (actual)

## Conditions studied

- Head and Neck Squamous Cell Cancer

## Interventions

- **BIOLOGICAL:** INO-3112
- **DEVICE:** CELLECTRA™-5P

## Key facts

- **NCT ID:** NCT02163057
- **Lead sponsor:** Inovio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-13
- **Primary completion:** 2017-01-23
- **Final completion:** 2017-01-23
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2021-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02163057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02163057, "Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02163057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*